GLP-1 receptor agonists × glycemic control

TrialDiabetes care2014

Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.

Julio Rosenstock et al.PubMed ↗Publisher ↗

What the trial testedas reported · 563 people · 2014

Range includes no effect

No clear effect on glycemic control

−0.16percentage points−0.32 to 0.00

As reported

difference −0.16 %, 95% CI −0.32 to 0.00

One number in the abstract

the abstract, start to end

with lispro; treatment difference, -0.16% (95% CI -0.32 to 0.00; 1.8

← favours treatmentfavours comparator →
could be chance
Glycemic control
−0.16−0.32 to 0.00
GLP-1 receptor agonistsInsulinGlycemic control
1 / 3

84 papers cite itlatest 60 shown

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 24898300